News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
220,822 Results
Type
Article (20387)
Company Profile (92)
Press Release (200337)
Multimedia
Podcasts (49)
Webinars (19)
Section
Business (74108)
Career Advice (840)
Deals (9631)
Drug Delivery (82)
Drug Development (19580)
Employer Resources (146)
FDA (3609)
Job Trends (6190)
News (99264)
Policy (7489)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (6)
Academia (1545)
Academic (2)
Accelerated approval (23)
ADA (17)
Adcomms (18)
Allergies (50)
Alliances (18460)
ALS (78)
Alzheimer's disease (771)
Antibody-drug conjugate (ADC) (180)
Approvals (3824)
Artificial intelligence (397)
ASCO (103)
Autoimmune disease (139)
Automation (35)
Bankruptcy (52)
Best Places to Work (4928)
BIO (31)
BIOSECURE Act (12)
Biosimilars (97)
BioSpace Insights (119)
Biotechnology (54)
Bladder cancer (61)
Brain cancer (22)
Breast cancer (259)
Cancer (1961)
Cardiovascular disease (206)
Career advice (770)
Career pathing (47)
CAR-T (125)
CDC (26)
Cell therapy (351)
Cervical cancer (19)
Clinical research (16669)
Collaboration (1088)
Commercialization (3)
Company closure (1)
Compensation (251)
Complete response letters (26)
COVID-19 (1043)
CRISPR (68)
C-suite (820)
Cystic fibrosis (59)
Data (2922)
Decentralized trials (2)
Denatured (31)
Depression (63)
Dermatology (51)
Diabetes (194)
Diagnostics (2745)
Digital health (25)
Diversity (10)
Diversity, equity & inclusion (37)
Drug discovery (226)
Drug pricing (58)
Drug shortages (7)
Duchenne muscular dystrophy (105)
Earnings (16866)
Editorial (24)
Employer branding (23)
Employer resources (126)
Events (33041)
Executive appointments (704)
FDA (4872)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (12)
Frontotemporal dementia (8)
Funding (1001)
Gene editing (123)
Generative AI (40)
Gene therapy (252)
GLP-1 (392)
Government (1457)
Guidances (136)
Healthcare (5258)
Hematology (67)
HIV (61)
Huntington's disease (27)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (37)
Immunology and inflammation (86)
Immuno-oncology (27)
Indications (72)
Infectious disease (1188)
Inflammatory bowel disease (93)
Inflation Reduction Act (8)
Influenza (48)
Intellectual property (94)
Interviews (123)
IPO (3821)
IRA (17)
Job creations (1342)
Job search strategy (645)
JPM (28)
Kidney cancer (5)
Labor market (105)
Layoffs (217)
Leadership (24)
Legal (1319)
Licensing (2)
Liver cancer (30)
Longevity (19)
Lung cancer (239)
Lymphoma (187)
Machine learning (32)
Management (45)
Manufacturing (489)
Marketing (1)
MASH (43)
Medical device (2893)
Medtech (2947)
Mergers & acquisitions (6397)
Metabolic disorders (461)
mRNA (86)
Multiple sclerosis (102)
NASH (9)
Neurodegenerative disease (174)
Neuropsychiatric disorders (30)
Neuroscience (1390)
Neurotech (1)
NextGen: Class of 2026 (2109)
Non-profit (1707)
Now hiring (84)
Obesity (215)
Opinion (156)
Ovarian cancer (61)
Pain (92)
Pancreatic cancer (70)
Parkinson's disease (137)
Partnered (21)
Patents (140)
Patient recruitment (219)
Peanut (19)
People (29259)
Pharmaceutical (22)
Pharmacy benefit managers (3)
Phase 1 (4896)
Phase 2 (6879)
Phase 3 (6500)
Pipeline (3492)
Policy (128)
Postmarket research (590)
Preclinical (2707)
Press Release (61)
Prostate cancer (110)
Psychedelics (31)
Radiopharmaceuticals (95)
Rare diseases (386)
Real estate (2658)
Recruiting (61)
Regulatory (6499)
Reports (50)
Research institute (1348)
Resumes & cover letters (109)
Rett syndrome (5)
RNA editing (11)
RSV (50)
Schizophrenia (66)
Series A (196)
Series B (122)
Service/supplier (6)
Sickle cell disease (46)
Special edition (15)
Spinal muscular atrophy (60)
Sponsored (19)
Startups (2083)
State (1)
Stomach cancer (6)
Supply chain (48)
Tariffs (17)
The Weekly (18)
Vaccines (369)
Venture capital (100)
Weight loss (126)
Women's health (70)
Worklife (20)
Date
Today (9)
Last 7 days (209)
Last 30 days (804)
Last 365 days (10328)
2026 (6741)
2025 (9883)
2024 (11662)
2023 (13325)
2022 (16893)
2021 (18821)
2020 (17038)
2019 (15447)
2018 (11081)
2017 (10698)
2016 (10477)
2015 (11366)
2014 (8410)
2013 (7287)
2012 (7754)
2011 (7877)
2010 (7328)
Location
Africa (337)
Alabama (36)
Alaska (4)
Arizona (112)
Arkansas (4)
Asia (12313)
Australia (2216)
California (4496)
Canada (1397)
China (454)
Colorado (224)
Connecticut (135)
Delaware (222)
Europe (34934)
Florida (633)
Georgia (137)
Hawaii (3)
Idaho (13)
Illinois (324)
India (54)
Indiana (348)
Iowa (16)
Japan (265)
Kansas (49)
Kentucky (16)
Louisiana (14)
Maine (12)
Maryland (422)
Massachusetts (3642)
Michigan (153)
Minnesota (227)
Mississippi (5)
Missouri (56)
Montana (6)
Nebraska (10)
Nevada (40)
New Hampshire (18)
New Jersey (1328)
New Mexico (19)
New York (1459)
North Carolina (719)
North Dakota (10)
Northern California (2445)
Ohio (151)
Oklahoma (12)
Oregon (23)
Pennsylvania (813)
Puerto Rico (11)
Rhode Island (18)
South America (405)
South Carolina (13)
Southern California (1591)
Tennessee (93)
Texas (651)
United States (16623)
Utah (100)
Vermont (1)
Virginia (122)
Washington D.C. (31)
Washington State (356)
West Virginia (1)
Wisconsin (102)
Wyoming (1)
220,822 Results for "roivant sciences gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
August 6, 2026
·
15 min read
Press Releases
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 24, 2026
·
3 min read
Press Releases
LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
July 17, 2026
·
5 min read
Press Releases
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026
·
23 min read
Immunology and inflammation
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.
March 31, 2026
·
4 min read
·
Tristan Manalac
Press Releases
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
·
4 min read
Patents
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant
The settlement, which requires Moderna to pay the plaintiffs $950 million upfront plus up to $1.3 billion in contingent commitments, is an outcome “better than feared,” according to analysts.
March 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 2, 2026
·
8 min read
Press Releases
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
February 8, 2026
·
20 min read
Press Releases
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
January 26, 2026
·
4 min read
1 of 22,083
Next
